Sen Lai, MD
Cardiology · Long Beach, CANPI 1740227040
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations.
Across 161 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Radius Health, Inc.$466
- Bayer$465
- Novartis$369
- Novo Nordisk$357
- Pfizer$342
- AstraZeneca$294
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,545100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Radius Health, Inc. | 19 | $466 |
| Bayer | 21 | $465 |
| Novartis | 19 | $369 |
| Novo Nordisk | 17 | $357 |
| Pfizer | 15 | $342 |
| AstraZeneca | 16 | $294 |
| Boehringer Ingelheim | 8 | $203 |
| Merck | 8 | $190 |
| Amgen | 9 | $188 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $112 |
| Lexicon Pharmaceuticals, Inc. | 4 | $108 |
| E.r. Squibb & Sons, L.L.C. | 5 | $108 |
| AbbVie | 2 | $59 |
| Gilead | 2 | $51 |
| Lilly USA, LLC | 2 | $42 |
| Dexcom, Inc. | 1 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| GSK | 1 | $24 |
| Shield Therapeutics Inc | 1 | $24 |
| Heartflow, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $16 |
How this compares
$3,558 in reported general payments places this provider in the 75th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 104 | $113,752 |
| OzempicSemaglutide | 98 | $97,165 |
| EliquisApixaban | 40 | $51,128 |
| JanuviaSitagliptin Phosphate | 56 | $44,945 |
| FarxigaDapagliflozin Propanediol | 33 | $37,274 |
| EntrestoSacubitril/Valsartan | 27 | $32,364 |
| TradjentaLinagliptin | 20 | $26,156 |
| VascepaIcosapent Ethyl | 36 | $20,006 |
| Repatha SureclickEvolocumab | 25 | $19,115 |
| Icosapent Ethyl | 42 | $15,922 |
| TrulicityDulaglutide | 11 | $14,639 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $7,255 |
| Febuxostat | 17 | $6,045 |
| Atorvastatin Calcium | 338 | $5,934 |
| Metformin Hcl | 238 | $3,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $203 | $139,907124 claims |
| Novo NordiskOzempic | $357 | $97,16598 claims |
| PfizerEliquis | $342 | $51,12840 claims |
| MerckJanuvia | $190 | $44,94556 claims |
| AstraZenecaFarxiga | $294 | $37,27433 claims |
| NovartisEntresto | $369 | $32,36427 claims |
| Lilly USA, LLCTrulicity | $42 | $14,63911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 cardiology providers in California.
Other cardiology in Long Beach
- Norman LeporBeverly Hills$1.9M
- Sanjay KaulLos Angeles$1.1M
- Ramtin AgahMountain View$361K
- Jamshid MaddahiLos Angeles$59K
- Bipin JoshiFresno$51K
- Anil ShahSanta Ana$49K
- Thomas KimSanta Ana$47K
- Hooman MadyoonLos Angeles$24K
- Lakhjit SandhuFresno$19K
- Prabhtej BraraSanta Monica$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.